This revolutionary 3D imaging technology is just starting to gain the attention of Wall Street.

Why little-known Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) could be the investment opportunity of the year.

Savvy investors know that one of the quickest ways to profit is by investing in a new medical technology that has the potential to impact the lives of millions. 

For example, early investors in Moderna (MNDR) saw the value of their shares skyrocket as a result of the new mRNA Covid-19 vaccine the Company developed.  The shares rose in price from $21 a share in March 2020 at the start of the pandemic, to over $400 a share by September 2021 – a gain of 1800% in just 17 months.

While not getting the attention it deserves, breast cancer is even more prevalent among women than Covid-19 has been among the general population. 

According to the American Cancer Society, approximately 1 in 8 women (13%) will be diagnosed with invasive breast cancer at some point in their lifetime.  In contrast, it’s estimated that roughly 10% of Americans, at least at the moment, have officially contracted Covid-19. 

In raw numbers, every year in the United States, 268,0001 women get the bad news – and 42,0002 die from the disease.

Yet now, an innovative medical imaging company is developing a revolutionary technology that is a possible game-changer and could potentially improve and even save the lives of thousands of women every year.

The Company is Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) .

Working with an award-winning research team at the University of California, Davis (UC Davis), and other top specialists in the U.S. and Canada, the Company’s engineers, medical physicists, and designers are developing what they believe is a major advancement in breast imaging and diagnostics.

More than $25 million has been invested across all aspects of this unique breast CT diagnostic system, with the majority of this capital spent on research and clinical studies at UC Davis Medical Center, funded primarily by the National Institutes of Health. 

At Last, a Breast Imaging Technology for the 21st Century!

The IzoView platform is unlike any other breast imaging technology currently on the market – and its potential as a platform is far greater than merely that of a diagnostic device. 

Instead of women standing in front of an old-fashioned x-ray machine that requires uncomfortable, vice-like breast compression, they lie on a comfortable tabletop and place their own breast in an opening in the table. 

Beneath the bed-like table, an advanced computed tomography (CT) camera moves around the breast in a 360-degree circle, taking approximately 500 images in just 10 seconds. 

Proprietary AI computer software then takes these 500 raw image slices of the non-compressed breast and reconstructs the slices into full 3D images of the entire breast.

Comparable to High-Resolution MRI Images, But at a Fraction of the Cost

Recent technological advancements allow the IzoView platform to generate clear, true 3D images.

These high-resolution 3D images of the breast are comparable in quality to images created by ultra-expensive Magnetic Resonance Imaging (MRI) scanners – yet for a fraction of the cost. 

And here’s the good news for investors looking to get in on the “next big thing” in medical device technology: Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) is now moving from the design phase to the clinical study prototype and FDA submission stage, which is where early investors can quickly see if they’ve struck a winner or not.

Four successive working breast CT models have been built and tested at UC Davis Medical Center, each incorporating efficiencies and new cutting-edge technological advancements as they became available.

The advancements include superior breast positioning design, ergonomic tabletop modifications, positioning aids, specialized x-ray detector and x-ray tube technologies, new x-ray beam shaping filters, and many other subtleties that improved the imaging system’s clinical performance and contributed to the current, very high-resolution imaging capability.

The Advantages of High-Resolution 3D Imaging Over Traditional Mammograms

There are many potential advantages of the 3D imaging system that Izotropic is developing over diagnostic x-ray mammograms as they are currently used.  The greater comfort and privacy are of paramount importance, but they are merely two of the many benefits of IzoView CT imaging for breast diagnostics. 

A traditional diagnostic x-ray mammogram can require up to 12 individual “views,” with each view taking up to 20 seconds of painful, sometimes agonizing compression to complete.  Between each view, a technician has to handle the patient’s breast as it is repositioned in the compression plates.  As a result, an x-ray mammogram can take between 20 and 45 minutes to complete.

What’s more, the images produced are often not ideal. Anatomical structures can be distorted, and there is no differentiation between macro-and micro-calcifications in the breast tissue – crucial for identifying potential tumors.

In addition, traditional diagnostic x-ray mammograms do not use contrast for tumor visualization.  That’s one reason why mammograms are only rated 73% sensitive in detecting tumors and only 44% sensitive for patients with dense breast tissue. 

Worse yet, 40% of women over age 40 have dense breast tissue.  That means x-ray mammograms can and often do miss a substantial number of abnormalities.

According to one recent study, old-fashioned mammograms can miss up to 15 percent6 of cancer tumors, and follow-up ultrasounds miss 2.3 percent, often because of dense breast tissue.

Izotropic’s 3D Imaging System Seeks to Overcome These Disadvantages

First, Izotropic Corporation’s (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZObreakthrough 3D imaging system eliminates compression altogether.

Natural breast orientation is preserved with the patient placing her own breast in the imaging cup, so there is no embarrassing handling by a technician.  This also ensures that there is excellent visualization with contrast. 

Further, the imaging procedure is over in a flash.  The system takes 500 high-resolution images in approximately 10 seconds with about the same level of radiation from just two traditional mammogram views. 

What’s more, Izotropic is developing new image reconstruction software utilizing the latest machine learning algorithms to deliver both high resolution and low noise images at low radiation dose levels. Aside from improved detection capabilities, IzoView is a potential solution for more precise margin analysis (viewing edges of a tumor), better “lesion characterization” (the detailed description of an abnormality), and higher spatial resolution, allowing radiologists to better differentiate internal breast structures.

Women and Doctors Eager for the “Next Stage” in Breast Health

As a result, the “buzz” is substantial around this potentially breakthrough technology in women’s health – and it’s not just investors that are so excited about the IzoView 3D imaging platform.

Patients are already asking when the technology will be available and for a good reason! 

The IzoView 3D imaging platform is…

  • A solution for Patients: Patients enjoy a pain-free, comfortable, and more private procedure that is over in seconds rather than in 20 to 45 minutes.
  • A solution for Doctors: Doctors benefit because the 3D visualization and contrast expand use cases and can aid diagnosis
  • A solution for Hospitals & Clinics: The 3D imaging system can improve patient throughput and attract more customers
  • A solution for Insurers: Could lower costs by lowering the number of false positives that lead to unnecessary (and costly) biopsies

Half of Women Will Likely Get a Devastating False Breast Cancer Diagnosis

False positives are common in breast imaging:  False positives are when old-fashioned mammograms reveal abnormalities in the breast tissue that later tests and biopsies reveal are actually benign and not cancerous tumors. About 50 percent of women who get annual mammograms over a ten-year period will have a false-positive finding at least once.

The problem is, these false positives cause tremendous stress and worry for thousands of women, not to mention unnecessary biopsy procedures – and the follow-up imaging exams and biopsies can cost tens of thousands of dollars per patient.

The market for Breast Imaging to Soar to $5.4 Billion by 2025

The market for Izotropic Corporation’s (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZOnew breast imaging platform is potentially enormous.  It’s estimated that the market for breast imaging technology will grow from $3.7 billion in 2020 to $5.4 billion by 202513.

What’s more, 40 million women receive a mammogram each year in the United States.  Of these, about 10 percent – or 4 million — are called back for expensive follow-up tests, such as diagnostic mammograms, tomosynthesis, ultrasound, MRI, and biopsies.

An advanced breast imaging technology like the one Izotropic is designing and submitting to the FDA could potentially save America’s struggling health care systems billions of dollars – and would be extremely attractive for hospitals and health care managers. 

A recent study found that the cost of follow-up imaging and diagnostic procedures after initial mammograms was more than $8 billion annually, just in the United States alone.

Fully Functioning Research Prototypes Now Being Tested

Izotropic Corporation’s breast CT imaging platform could allow radiologists to view 3D images comparable to MRI as part of the initial, low-cost, low-dose routine breast cancer imaging in the future– as many as 40 million per year – and not have to order and then wait for expensive follow-up tests.

Right now, Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) is the only public Company developing an advanced breast CT imaging platform for diagnostic use based on clinically validated research prototypes.  This alone is a reason why many investors are excited by this Company’s potential.

U.S. Government Funding and Patents

In addition to investor funds, approximately $20 million in U.S. government grants has been invested to develop this ground-breaking, potentially life-saving technology at the UC Davis Medical Center in Sacramento, California. Izotropic is well-funded to advance important initiatives, with news flow expected to be strong in the months ahead.

The researchers developing the IzoView platform have 10 unique U.S. patents and patent-pending applications, including for using breast CT to measure breast density, to perform robotic guided biopsies, and to incorporate a 3D-beam modulation filter that shapes IzoView’s x-ray beam to match the shape of the patient’s breast and further reducing the radiation dose.

The patent for biopsies is particularly noteworthy.  71 percent of the 1.6 million breast biopsies performed in the U.S. are found to be negative at the cost of $2.2 billion.14

Looking to the Future

Izotropic is setting up its long-term platform strategy to increase customer appeal with more add-ons and building in additional revenue streams. After market entrance as a diagnostic device, the Company plans to offer solutions across the gamut of breast health care, including screening and diagnosis in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstruction surgery.

A CEO and Scientific Advisory Team Like No Other

In addition, the management of Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) is fully committed to bringing this disruptive imaging technology to market.

A Low-Priced Stock with Huge Potential

As a publicly-traded company only founded in 2016, shares of Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO) are currently selling for around a dollar – but likely not for long. The stock was up 455% in 2020 and is expected to garner a lot more attention throughout 2021 and 2022.

Only about 40 million shares are outstanding, meaning the current market capitalization is tiny given the “disruptive” nature of Izotropic’s technology and the fact it’s the only publicly traded Company developing this kind of platform to address the growing problem of breast cancer.

Making Lemonade Out of Lemons with Covid-19

Izotropic Corporation is a company that figured out a way to use the economic disruptions of the Covid-19 pandemic to its advantage. 

As Covid-19 set in, the Company took advantage of the delays in performing clinical studies and supply chain disruptions to design an even better product. 

As newer, next-generation components became available, the Company incorporated these improvements in its imaging system.  The Company spent the past two years making additional investments and expanding its engineering capabilities, onboarding personnel, and investigating and finalizing the IzoView platform strategy.

That means, as the Company enters the clinical study phase and FDA submission phases of its product development, it expects to deliver a better performing technology with a broader product offering and a more competitively priced Breast CT system.

Getting Ready to Launch

The Company is completing the final design for the development of its IzoView platform – and is preparing for a clinical study to collect data that it will use for an FDA application for approval of an indication for use as a diagnostic device.

When FDA approval has been awarded, the Company will ramp up marketing of its revolutionary IzoView platform to the thousands of hospitals and clinics throughout the United States. The Company is already participating in the FDA’s Center for Devices & Radiological Health Payor Communication Task Force program and can use historical trial data in discussions with insurance payers to demonstrate patient benefits for insurance coverage of the Company’s new IzoView platform.

Hundreds of Millions of Women Will Demand This Technology

Women worldwide have already begun hearing about a brand-new, easy, and compression-free way to do breast imaging – lying comfortably for a few seconds on an imaging table rather than standing in front of an x-ray machine while their breasts are compressed between metal plates.

Once word gets out, even more, the demand for this disruptive new technology will likely be intense – and all bets are off for shares in Izotropic Corporation (OTCQB: IZOZF | CSE: IZOOTCQB: IZOZF | CSE: IZO).

The time to investigate this Company is now, before it submits to the FDA, with a major breakthrough in breast imaging technology that could potentially change the lives of millions of women and their families.

[optin-monster slug="nbr5hjk8cmim0bunhatv"]

415% x 40 million mammograms = 6 million. That seems high. 15% of 4 million follow-up exams = 600,000
14Corporate Presentation, September 2020, p. 10.
15Ibid., p. 15



This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Publisher has not been compensated by any of the profiled companies. The Publisher’s compensation for articles appearing on this website is as follows:

  • The Publisher has been paid approximately $500 per week while the advertisement campaign was active by Think Ink Media as compensation to host the article profiling Izotropic Corporation.(“the Company”).

The Publisher has not participated in the creation of the content of any articles appearing on this website and so cannot guarantee the accuracy or completeness of the information in any of the articles. The Publisher expressly disclaims any responsibility or liability for statements made in any of the articles.

SHARE OWNERSHIP. The Publisher does not own any shares of any profiled company and has no information concerning share ownership by others of any profiled company. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES. This website enables users to link to external websites not under the control of The Publisher. The Publisher has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Publisher expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY. The Market Tactic is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind.